Communicating the importance of managed care pharmacy is a key part of AMCP’s work. Using AMCP policies as a basis for their work, AMCP staff and volunteers provide comments, analysis and testimony to Congress and other federal and state agencies on how proposed regulations and laws impact managed care pharmacy and the patients we serve.
Archives
5/14/2012
» AMCP comments to the FDA on direct-to-consumer (DTC) television advertisements
» AMCP comments to the FDA on issues that may result in a prescription drug or biological product shortage
5/7/2012
» AMCP Joins Group Letter to House Energy and Commerce on Efforts to Reduce Drug Shortages
» AMCP comments to CMS on Stage 2 of the Electronic Health Record Incentive Program
» AMCP provides input to HHS Office of the Surgeon General of the United States Public Health Service on prescription medication adherence
» AMCP comments to the FDA on conditions of safe use to expand which drug products can be considered nonprescription
4/24/2012
» AMCP joins sign on letter supporting Senate drug shortages language
4/23/2012
» AMCP sends final comments to Senate HELP on PDUFA reauthorization
4/16/2012
» AMCP summary of the CMS Final Rule to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for 2013
4/12/2012
» AMCP comments to the National Quality Forum (NQF) Measures Application Partnership (MAP) final report to HHS on measuring healthcare quality for the dual eligible population
» AMCP provides comments to the FDA on Q&As regarding implementation of the Biologics Price Competition and Innovation Act of 2009 (BPCI Act)
» AMCP provides comments to the FDA on quality considerations in demonstrating biosimilarity to a reference protein product.
4/11/2012
» AMCP Summary of Calendar Year (CY) 2013 Call Letter: Items of Importance to Managed Care Pharmacy
4/9/2012
» AMCP provides comments to Senate HELP Committee on the reauthorization of the Prescription Drug User Fee Act
» AMCP letter to House Judiciary Subcommittee on H.R. 1946, the "Preserving Our Hometown Independent Pharmacy Act of 2011"
4/6/2012
» AMCP Joins Group Letter to Senate HELP Committee on Drug Shortages
3/26/2012
» AMCP letter to House Energy and Commerce Committee on PDUFA reauthorization
» AMCP letter to Senate Committee on Health, Education, Labor, and Pensions on PDUFA reauthorization
» AMCP comments to the FDA on communications and activities related to off-label uses of marketed products and use of products not yet legally marketed
» AMCP comments to the FDA on the Draft Guidance for Industry; responding to unsolicited requests for off-label information about prescription drugs and medical devices
3/23/2012
» AMCP letter to Senate Health, Education, Labor, and Pensions Committee on drug shortages
» AMCP letter to House Energy and Commerce Committee on drug shortages
» AMCP letter to National Governors Association
3/22/2012
» Marissa Schlaifer, R.Ph., AMCP's Director of Pharmacy Affairs testifimony to the FDA on behalf of the Academy on Using Innovative Technologies and Other Conditions of Safe Use To Expand Which Drug Products Can Be Considered Nonprescription (Testimony Presentation Slides)
3/16/2012
» AMCP joins nine pharmacy associations to comment to the American Academy of Family Physicians (AAFP) on their recently released position paper Pharmacists
3/14/2012
» AMCP comments to The National Committee for Quality Assurance (NCQA) on proposed changes to the 2013 Healthcare Effectiveness Data and Information Set (HEDIS) Measures.
» AMCP comments to the FDA on the Healthcare Professional Survey of Prescription Drug Promotion
» AMCP comments to the Patient-Centered Outcomes Research Institute (PCORI) on its Draft National Priorities for Research and Research Agenda, Version 1
3/2/2012
» AMCP comments to CMS on the draft Advance Notice of Changes for Calendar Year 2013 in the 2013 Call Letter
2/22/2012
» HHS response to AMCP's comment letter on essential health benefits associated with the affordable insurance Exchanges
» HHS response to AMCP's comment letter on coverage of preventive services under the Affordable Care Act (ACA)
2/13/2012
» AMCP comments to the FDA on New Drug; Revision of Postmarketing Reporting Requirements - Discontinuance
2/7/2012
» AMCP summary of the CMS Proposed Rule on Medicaid Program Covered Outpatient Drugs
2/3/2012
» AMCP comments to the Patient-Centered Primary Care Collaborative (PCPCC) on the proposed medication management guidelines
1/31/2012
» AMCP comments to CMS on proposed changes to the Part D Reporting Requirements for Contract Year 2013
» AMCP comments to HHS on the Essential Health Benefits Bulletin issued by the Center for Consumer Information and Insurance Oversight (CCIIO) on December 16, 2011.
1/20/2012
» AMCP comments to NQF on Patient Outcomes: All Cause Readmissions Expedited Review 2011: A Consensus Report
1/19/2012
» AMCP comments on NQF Measure Application Partnership (MAP) Pre-Rulemaking Report
1/13/2012
» AMCP comments to the Centers for Medicare & Medicaid Services (CMS) on enhancements to the Part C and Part D plan ratings
1/5/2012
» The Department of Labor responds to AMCP on coverage of preventive services under the Affordable Care Act (ACA)
1/4/2012
» AMCP comments to the Food and Drug Administration (FDA) on the proposed recommendations for enactment of the Generic Drug User Fee Act (GDUFA)